Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of neural transmission

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00702-017-1821-9PMID 29222591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease

  2018cited by this paper
• Transcriptional network analysis in frontal cortex in Lewy body diseases with focus on dementia with Lewy bodies

  2018cited by this paper
• Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium

  2018cited by this paper
• White matter hyperintensities on MRI in dementia with Lewy bodies, Parkinson's disease with dementia, and Alzheimer's disease.

  2018cited by this paper
• Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?

  2018influential reference
• Cognitive and behavioral disorders in Parkinson’s disease: an update. I: cognitive impairments

  2018cited by this paper
• Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta‐analyses

  2018cited by this paper
• Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach

  2018cited by this paper
• Critical appraisal of pathology transmission in the &agr;‐synuclein fibril model of Lewy body disorders

  2018cited by this paper
• New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases.

  2018cited by this paper
• Dementia with Lewy Bodies and Parkinson Disease Dementia: It is the Same Disease!

  2018cited by this paper
• Genetics of Synucleinopathies.

  2018influential reference
• Distinct patterns of amyloid‐dependent tau accumulation in Lewy body diseases

  2018cited by this paper
• β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease

  2017cited by this paper
• Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms

  2017cited by this paper
• Lewy Body Disorders.

  2017cited by this paper
• 18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment

  2017cited by this paper
• An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease

  2017cited by this paper
• Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study.

  2017cited by this paper
• Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias

  2017cited by this paper
• Correlation between clinical symptoms and striatal DAT uptake in patients with DLB

  2017cited by this paper
• Propagation of alpha-synuclein pathology from the olfactory bulb: possible role in the pathogenesis of dementia with Lewy bodies

  2017cited by this paper
• Duration and Pathologic Correlates of Lewy Body Disease

  2017cited by this paper
• Diagnostic utility of cerebrospinal fluid α‐synuclein in Parkinson's disease: A systematic review and meta‐analysis

  2017cited by this paper
• Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

  2017cited by this paper
• Parkinson's disease susceptibility variants and severity of Lewy body pathology.

  2017cited by this paper
• The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward

  2017cited by this paper
• Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB

  2017cited by this paper
• New cerebrospinal fluid biomarkers in Alzheimer’s disease

  2017cited by this paper
• Long reaction times are associated with delayed brain activity in lewy body dementia

  2017cited by this paper
• Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

  2017cited by this paper
• The influence of hippocampal atrophy on the cognitive phenotype of dementia with Lewy bodies

  2017cited by this paper
• An update on the genetics of dementia with Lewy bodies.

  2017cited by this paper
• Author response: Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB

  2017cited by this paper
• Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study

  2017cited by this paper
• Diagnosis of dementia with Lewy bodies: can 123I-IMP and 123I-MIBG scintigraphy yield new core features?

  2017cited by this paper
• Synaptic proteins in CSF relate to Parkinson’s disease stage markers

  2017cited by this paper
• Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies

  2017cited by this paper
• Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer’s disease: An autopsy-confirmed study

  2017cited by this paper
• An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias

  2017cited by this paper
• Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies

  2017cited by this paper
• Regional Overlap of Pathologies in Lewy Body Disorders

  2017cited by this paper
• Cognitive and behavioral disorders in Parkinson’s disease: an update. II: behavioral disorders

  2017cited by this paper
• Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature

  2017cited by this paper
• Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms

  2017cited by this paper
• A new potential biomarker for dementia with Lewy bodies

  2017cited by this paper
• Natural course of mild cognitive impairment in Parkinson disease

  2017cited by this paper
• Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia

  2017cited by this paper
• Non-pharmacological interventions for Lewy body dementia: a systematic review

  2017cited by this paper
• PITX3 genotype and risk of dementia in Parkinson's disease: A population-based study.

  2017cited by this paper
• Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse

  2017cited by this paper
• Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

  2017cited by this paper
• Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy

  2017cited by this paper
• Cardiac sympathetic denervation and dementia in de novo Parkinson's disease: A 7-year follow-up study.

  2017cited by this paper
• Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort

  2017cited by this paper
• Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies.

  2017cited by this paper
• GBA mutations in Parkinson disease: earlier death but similar neuropathological features

  2017cited by this paper
• 18F-FDG PET in Posterior Cortical Atrophy and Dementia with Lewy Bodies

  2017cited by this paper
• Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease

  2017cited by this paper
• Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

  2017cited by this paper
• Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature

  2017cited by this paper
• TDP‐43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing

  2017cited by this paper
• Polymorphisms in dopamine‐associated genes and cognitive decline in Parkinson's disease

  2017cited by this paper
• Does attentional dysfunction and thalamic atrophy predict decline in dementia with Lewy bodies?

  2017cited by this paper
• Synaptic phosphorylated &agr;-synuclein in dementia with Lewy bodies

  2017cited by this paper
• Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

  2017cited by this paper
• Hallucinations and the spectrum of psychosis in Parkinson's disease.

  2017cited by this paper
• Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.

  2017cited by this paper
• Cognitive decline in Parkinson disease

  2017cited by this paper
• Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff

  2017cited by this paper
• Therapeutic approaches to target alpha-synuclein pathology.

  2017cited by this paper
• Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis

  2017cited by this paper
• Exploring the Phenotype in Mild Cognitive Impairment to Aid the Prediction of Those at Risk of Transitioning to Parkinson Disease and Dementia With Lewy Bodies

  2017cited by this paper
• Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology

  2017cited by this paper
• An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease

  2017cited by this paper
• A clinicopathological approach to the diagnosis of dementia

  2017cited by this paper
• The New Diagnostic Criteria for Parkinson's Disease.

  2017influential reference
• Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case

  2017cited by this paper
• Prodromal Dementia with Lewy Bodies and Prodromal Alzheimer’s Disease: A Comparison of the Cognitive and Clinical Profiles

  2017cited by this paper
• The heart of PD: Lewy body diseases as neurocardiologic disorders.

  2017cited by this paper
• The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy

  2017cited by this paper
• Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts

  2017cited by this paper
• Population‐based analysis of pathological correlates of dementia in the oldest old

  2017cited by this paper
• Like prions: the propagation of aggregated tau and &agr;-synuclein in neurodegeneration

  2017cited by this paper
• Interactions of pathological proteins in neurodegenerative diseases

  2017cited by this paper
• Distinct brain metabolic patterns separately associated with cognition, motor function, and aging in Parkinson's disease dementia.

  2017cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2017cited by this paper
• Striatal dopamine in Parkinson disease: A meta‐analysis of imaging studies

  2017cited by this paper
• Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind.

  2017influential reference
• Alzheimer's disease pathology in synucleinopathies.

  2017cited by this paper
• Neuronal Loss and Α-Synuclein Pathology in the Superior Colliculus and Its Relationship to Visual Hallucinations in Dementia with Lewy Bodies.

  2017cited by this paper
• Impact of multiple pathologies on the threshold for clinically overt dementia

  2017influential reference
• Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism: The Rotterdam Study

  2017cited by this paper
• Clinical and neuroimaging characteristics of Chinese dementia with Lewy bodies

  2017cited by this paper
• Synthesis and biological evaluation of novel radioiodinated benzimidazole derivatives for imaging α-synuclein aggregates.

  2017cited by this paper
• Differential diagnosis between patients with probable Alzheimer’s disease, Parkinson’s disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features

  2017cited by this paper
• The prognosis of dementia with Lewy bodies.

  2017cited by this paper
• Symptoms associated with Lewy body disease in mild cognitive impairment

  2017cited by this paper
• Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

  2017cited by this paper
• Metabolic correlate of memory-deficit awareness in dementia with Lewy bodies: Implication in cortical midline structure.

  2017cited by this paper

• HCA2 activation confers neuroprotection in Parkinson's disease models by suppressing oxidative stress and ferroptosis via the Nrf2/MGST1/GPX4 pathway.

  2026cites this paper
• Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson's disease.

  2026cites this paper
• HDL cholesterol indicates neurodegenerative vulnerability in dementia with lewy bodies.

  2026cites this paper
• Mitochondrial D-loop region methylation differentiates Parkinson's disease from atypical parkinsonism and Parkinson's disease dementia.

  2026cites this paper
• Genetic and Hormonal Contributions to Psychosis Symptoms in Alzheimer’s Disease: A Sex-Stratified Analysis

  2026cites this paper
• Comparison of Quantitative-Electroencephalogram (q-EEG) Measurements Between Patients of Dementia with Lewy Bodies (DLB) and Parkinson Disease Dementia (PDD)

  2025cites this paper
• Immune Profiling in Early Cognitive Disorders (IMPRINT) study protocol: a longitudinal cohort study exploring biomarkers of inflammation in early dementia with Lewy bodies and Alzheimer’s disease, as part of the Dementias Platform UK

  2025cites this paper
• Symptom diagnosis codes informing under-diagnosis of Lewy body dementia in Medicare beneficiaries from different ethnoracial backgrounds

  2025cites this paper
• Effects of glucocerebrosidase gene variations on the risk of Parkinson’s disease dementia: a meta-analysis

  2025cites this paper
• α-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers.

  2025cites this paper
• Case of a 57‐year‐old woman with acute confusion and inability to recognize her husband

  2025cites this paper
• Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy Bodies

  2025cites this paper
• Phosphoproteome modifications and cortical circuit dysfunction are linked to the early-stage progression of alpha-synuclein aggregation

  2025cites this paper
• DCARD checklist: A simple screening tool for Lewy body disease-related early symptoms in memory clinic.

  2025cites this paper
• Cortical α-synuclein pathology induces cell autonomous neuronal hypoactivity and compensatory circuit changes in a model of early Lewy body dementia

  2025cites this paper
• Staging and markers in Parkinson’s disease and Lewy body disorders: narrative review

  2025cites this paper
• A Comprehensive Framework for Parkinson's Disease Detection Using Spiral Drawings and Advanced Machine Learning Techniques

  2025cites this paper
• Identification of Common Brain Protein and Genetic Loci Between Parkinson's Disease and Lewy Body Dementia

  2025cites this paper
• Elevated cerebrospinal fluid levels of SERPIN E1 in participants with lewy body diseases

  2025cites this paper
• The compensatory effect of education as revealed by resting-state electroencephalographic alpha rhythms in patients with dementia due to Parkinson's disease: findings from an exploratory study.

  2025cites this paper
• Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217

  2025cites this paper
• Does Platelet Transcriptome Dysregulation Across the Lewy Body Continuum Mirror Neuronal Dysfunction?

  2025cites this paper
• CSF Biomarker‐Based Cognitive Trajectories in Parkinson's Disease‐Subjective Cognitive Decline

  2025cites this paper
• Automated Advancements and Synergistic Challenges in Multi-Modal Clinical Assessments for Alzheimer’s Disease Diagnosis: A Comprehensive Review and Meta-Analysis

  2025cites this paper
• Multiplex Proteomics of Lewy Body Dementia Reveals Cerebrospinal Fluid Biomarkers of Disease Pathology and Progression

  2025cites this paper
• The causal role of lipids in dementia: A Mendelian randomization study

  2025influential citation
• Rational design of structure‐based vaccines targeting misfolded alpha‐synuclein conformers of Parkinson's disease and related disorders

  2024cites this paper
• An Epigenetic Manifestation of Alzheimer's Disease: DNA Methylation

  2024cites this paper
• Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.

  2024cites this paper
• The Imbalance of Homocysteine, Vitamin B12 and Folic Acid in Parkinson Plus Syndromes: A Review beyond Parkinson Disease

  2024cites this paper
• Comparison of Brain Activity between Patients with Parkinson Disease Dementia and Patients Affected by Dementia with Lewy Body through EEG Analysis

  2024cites this paper
• Factors associated with care‐resistant behavior in the National Alzheimer's Coordinating Center's Uniform Data Set

  2024cites this paper
• AIMP2 accumulation in brain leads to cognitive deficits and blood secretion in Parkinson’s disease

  2024cites this paper
• FNDC5/Irisin in dementia and cognitive impairment: update and novel perspective

  2024cites this paper
• Modulating the cholinergic system—Novel targets for deep brain stimulation in Parkinson's disease

  2024influential citation
• Peripheral immune profile in drug-naïve dementia with Lewy bodies

  2024cites this paper
• A general clinical overview of the non-motor symptoms in Parkinson's disease: Neuropsychiatric symptoms.

  2024cites this paper
• Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians

  2024cites this paper
• Patterns of tau, amyloid and synuclein pathology in ageing, Alzheimer’s disease and synucleinopathies

  2024cites this paper
• Efficacy and safety of hyperbaric oxygen therapy for Parkinson’s disease with cognitive dysfunction: protocol for a systematic review and meta-analysis

  2024cites this paper
• Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions

  2024cites this paper
• Cognition and Quality of Life in Parkinson's Disease

  2024cites this paper
• Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease

  2024cites this paper
• Neuropsychological and neuroanatomical underpinnings of the face pareidolia errors on the noise pareidolia test in patients with mild cognitive impairment and dementia due to Lewy bodies

  2024cites this paper
• Network Proteomics of the Lewy Body Dementia Brain Reveals Presynaptic Signatures Distinct from Alzheimer’s Disease

  2024cites this paper
• A Systematic Review of Genetic, Clinical, and Gender Associated Aspects of the SNCA Gene in Familial Parkinson’s Disease

  2024cites this paper
• [Dementia with Lewy bodies and Parkinson disease dementia, their diagnoses and treatment strategies].

  2024cites this paper
• Rhythmic auditory stimulation for motor rehabilitation in Parkinson’s disease

  2024cites this paper
• Accumulation of aggregated alpha-synuclein in neural tissue structures in neurodegenerative diseases

  2024cites this paper
• Unveiling autonomic failure in synucleinopathies: Significance in diagnosis and treatment.

  2024cites this paper
• Deficits in or Preservation of Basic Number Processing in Parkinson's Disease? A Registered Report

  2024cites this paper
• Apolipoprotein E Gene in α-Synucleinopathies: A Narrative Review

  2024cites this paper
• Comparison of univariate and multivariate analyses for brain [18F]FDG PET data in α-synucleinopathies

  2023cites this paper
• Histological Study on the Thickness of Gray Matter at the Summit and Bottom of Folium in Different Age Groups of Bangladeshi People

  2023cites this paper
• Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia

  2023cites this paper
• Clinical trials for cognition in Parkinson's disease: Where are we and how can we do better?

  2023cites this paper
• The ‘α-synucleinopathy syndicate’: multiple system atrophy and Parkinson’s disease

  2023cites this paper
• Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease.

  2023cites this paper
• Tau in dementia with Lewy bodies

  2023cites this paper
• A Preliminary Comparison of the Methylome and Transcriptome from the Prefrontal Cortex Across Alzheimer’s Disease and Lewy Body Dementia

  2023cites this paper
• CEST 2022-three-dimensional amide proton transfer (APT) imaging can identify the changes of cerebral cortex in Parkinson's disease.

  2023cites this paper
• Mild cognitive impairment in dementia with Lewy bodies: an update and outlook

  2023cites this paper
• Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions

  2023cites this paper
• Patient-specific multi-modal modeling uncovers neurotransmitter receptor involvement in motor and non-motor axes of Parkinson's disease

  2023cites this paper
• Identification of key genes and signaling pathways associated with dementia with Lewy bodies and Parkinson's disease dementia using bioinformatics

  2023cites this paper
• Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials

  2023cites this paper
• Vinpocetine prevents rotenone-induced Parkinson disease motor and non-motor symptoms through attenuation of oxidative stress, neuroinflammation and α-synuclein expressions in rats.

  2023cites this paper
• Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration.

  2023cites this paper
• Supercomplex formation of mitochondrial respiratory chain complexes in leukocytes from patients with neurodegenerative diseases.

  2023cites this paper
• Clinical biomarkers for Lewy body diseases

  2023cites this paper
• Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks

  2023cites this paper
• Drug Discovery and Development Targeting Dementia

  2023cites this paper
• Elucidating distinct molecular signatures of Lewy body dementias.

  2023cites this paper
• An Overview of Gastrointestinal Dysfunction in Parkinsonian Syndromes

  2023cites this paper
• T Lymphocytes and Their Potential Role in Dementia with Lewy Bodies

  2023cites this paper
• Fluid biomarkers in Alzheimer's disease.

  2023cites this paper
• The Common Denominators of Parkinson’s Disease Pathogenesis and Methamphetamine Abuse

  2023cites this paper
• A comprehensive review on detection and classification of dementia using neuroimaging and machine learning

  2023cites this paper
• Current Treatments and New, Tentative Therapies for Parkinson’s Disease

  2023cites this paper
• The Effects of Andrographis paniculata (Burm.F.) Wall. Ex Nees and Andrographolide on Neuroinflammation in the Treatment of Neurodegenerative Diseases

  2023cites this paper
• Distinct amyloid-dependent patterns of nigra dopamine depletion in Lewy body diseases

  2023cites this paper
• Non-Coding RNAs as Key Players in the Neurodegenerative diseases: Multi-platform Strategies and Approaches for exploring the Genome's Dark Matter.

  2023cites this paper
• Specific neuropsychiatric symptoms are associated with functional decline trajectories in Alzheimer’s disease and Lewy body dementia: a five-year follow-up study

  2023cites this paper
• Differential Neuropathology, Genetics, and Transcriptomics in Two Kindred Cases with Alzheimer’s Disease and Lewy Body Dementia

  2022cites this paper
• Morphological basis of Parkinson disease-associated cognitive impairment: an update

  2022cites this paper
• Pathological characterization of a novel mouse model expressing the PD-linked CHCHD2-T61I mutation

  2022cites this paper
• Sex and gender differences in dementia.

  2022cites this paper
• Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies

  2022cites this paper
• One Autopsy Proved Neocortical Lewy Body Disease Without the Involvement of the Olfactory Bulb and Brainstem

  2022cites this paper
• Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice

  2022cites this paper
• Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases

  2022cites this paper
• Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update

  2022cites this paper
• Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer’s disease topography

  2022cites this paper
• The presence and co-incidence of geriatric syndromes in older patients with mild-moderate Lewy body dementia

  2022cites this paper
• Deep phenotyping for precision medicine in Parkinson's disease

  2022cites this paper
• Caffeine Consumption and Dementia: Are Lewy Bodies the Link?

  2022cites this paper
• Disrupted myelination network in the cingulate cortex of Parkinson's disease

  2022cites this paper
• Aquaporin-4 and Cognitive Disorders

  2022cites this paper
• Caring for patients with cognitive dysfunction, fluctuations and dementia caused by Parkinson's disease.

  2022cites this paper
• Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

  2022cites this paper